StockNews.com Initiates Coverage on Oncternal Therapeutics (NASDAQ:ONCT)

Analysts at StockNews.com assumed coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a research report issued on Saturday. The firm set a “hold” rating on the stock.

Several other equities analysts have also commented on ONCT. Northland Capmk lowered shares of Oncternal Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 12th. Brookline Capital Management reissued a “hold” rating on shares of Oncternal Therapeutics in a research report on Thursday, September 12th. Finally, Northland Securities restated a “market perform” rating and set a $2.00 price target on shares of Oncternal Therapeutics in a research report on Thursday, September 12th. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $10.00.

Oncternal Therapeutics Price Performance

NASDAQ ONCT opened at $0.53 on Friday. The stock has a market capitalization of $1.56 million, a P/E ratio of -0.05 and a beta of 1.18. The firm’s 50-day moving average is $1.06 and its two-hundred day moving average is $3.72. Oncternal Therapeutics has a 12 month low of $0.53 and a 12 month high of $13.14.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.